Doxorubicin

Doxorubicin is one of the most effective cytotoxic drugs used to treat various types of malignant tumors. This drug is derived from the bacteria Streptomyces peucetius caesius and is an antibiotic containing an anthracycline.

Doxorubicin affects the DNA and RNA of cells, which leads to inhibition of their growth and reproduction. It is used to treat leukemia, sarcoma, breast cancer, ovarian cancer, lung cancer, stomach cancer, bladder cancer and other types of tumors.

Doxorubicin is given by injection or intravenous infusion in a hospital under the supervision of a doctor. Side effects of the drug may include suppression of bone marrow function, baldness, disruption of the gastrointestinal tract, damage to the heart muscle, and others.

Despite its effectiveness, doxorubicin can cause toxic effects on the cardiovascular system, so its use should be under close medical supervision.

The trade name of doxorubicin is Adriamycin. It is one of the most common and effective drugs for treating cancer and is widely used in clinical practice. However, like any medicine, doxorubicin should only be prescribed by a doctor and used with caution.

Doxorubicinum is an antitumor antibiotic alkaloid of natural origin produced by Streptomyces peucetius var. caesius.

Synonyms: Adriamycin, Doxal, Adriblastin, Adriamun, Adriablastin.

Doxorubicin is one of the most effective anticancer drugs that is widely used in medicine to treat various types of cancer, including breast cancer, lung cancer, prostate cancer, leukemia and other types of malignant tumors.

The main mechanism of action of doxorubicin is its ability to inhibit the synthesis of DNA and RNA in tumor cells, which leads to their death. Doxorubicin also has a cytostatic effect, i.e. the ability to cause cell damage, which can also lead to their death.

Depending on the dose and treatment regimen, doxorubicin can cause various side effects, such as suppression of bone marrow functions (aplasia, myelosuppression), baldness (alopecia), disruption of the functioning of the gastrointestinal tract (nausea, vomiting, diarrhea), damage to the heart muscle ( myocardial infarction, arrhythmias).

Doxorubicin is administered intravenously or intramuscularly as a solution. The standard dose for adults is 60-75 mg/m2 every 3-4 weeks. However, the dose may be adjusted depending on the individual patient and his response to treatment.

It is important to note that doxorubicin has a number of serious side effects, so before starting treatment, it is necessary to conduct a full examination of the patient and evaluate the possible risks and benefits. In addition, treatment should be carried out under the supervision of a physician, who will monitor the patient's condition and adjust the dosage if necessary.